UK Researchers Find Virus that Triggers Burkitt's Lymphoma
The virus that kickstarts Burkitt's lymphoma (a very rare type of non-Hodgkin's lymphoma diagnosed in around 2% of lymphoid-based cancers among people aged 13-24) has been unmasked by researchers at Cancer Research UK's Institute for Cancer Studies at the University of Birmingham.
They say that the Epstein-Barr virus (EBV), a very common but dormant virus found harmlessly in 90% of adults, may be responsible for triggering Burkitt's lymphoma in young people if their immune system's B lymphocyte cells have already been genetically compromised by a predisposition towards cancer.
In other words, if those cells are already predisposed towards lymphoma, the odds of developing Burkitt's is greatly increased if those cells also become infected by the EBV.
According to the research, "In some tumors [EBV causes Burkitt's] by switching on a protein that is usually inactive when the virus is dormant."
More information is available at Cancer Research UK's press release site.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
